On 12 October 2017, orphan designation (EU/3/17/1941) was granted by the European Commission to Capnia (UK) Ltd, United Kingdom, for diazoxide choline for the treatment of Prader-Willi syndrome.

In December 2017, Capnia (UK) Ltd changed name to Soleno Therapeutics UK Ltd.

The sponsorship was transferred to Soleno Therapeutics Europe Limited, Ireland, in July 2019.

Key facts

Active substance
diazoxide choline
Disease / condition
Treatment of Prader-Willi syndrome
Date of first decision
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Soleno Therapeutics Europe Limited
14 Saint Audoen's Terrace
Dublin 8 D08 W6K0

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating